Risk Sharing Agreements (RSAs) : Can "Innovative" Outcomes Based Contracts work?

There is a lot of buzz around a recent variation of Risk Sharing Agreements (RSAs) called “innovative” outcomes-based contracts, especially as more gene therapies receive approval. Several multimillion-dollar price-tag drugs have recently gained regulatory approval, with a record number of new cell and gene therapies (CGTs) up for regulatory decisions over the coming 2 years. There is significant logistical complexity in administering these shared-risk contracts.

Listen to our on-demand webinar where industry experts discuss key topics related to RSAs that include:
- The rising use of RSAs across geographies
- Novel pricing strategies like outcome-based risk-sharing agreements
- Numerous commercial, operational, financial and regulatory challenges
- Data-driven insights to inform strategy and implementation of risk-sharing agreements
- In-Silico Ph-4 RWE use case application

Panelists:
Luca Morolotti - Vice President, International Access & New Products, MSD
Khalid Mirza - Global Market Access & Pricing, Oncology, Daiichi Sankyo, Inc.
Paul Goudreau - Senior Vice President, Value-based Healthcare, Actu-Real Inc.

Moderator:
Madhur Garg - Vice President & Global Head, RWE, MA & HEOR

Agenda:
Introductions: 5 mins
Case Studies: 30 mins
Panel Discussion: 15 mins
Q&A: 10 mins